Literature DB >> 25194333

Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis.

Theodoros Dimitroulas1, Aamer Sandoo2, James Hodson3, Jacqueline Smith4, Vasileios F Panoulas5, George D Kitas6.   

Abstract

OBJECTIVE: The aim of our study was to determine whether Dimethylarginine Dimethylaminohydrolase (DDAH) 1 and 2 gene polymorphisms - the main enzyme involved in ADMA degradation - are associated with high Asymmetric Dimethylarginine (ADMA) levels in Rheumatoid Arthritis (RA).
METHODS: Serum ADMA levels were measured in 201 individuals with RA [155 females median age 67 (59-73)]. Four tag SNPs in DDAH1 gene and 2 in the DDAH2 gene were genotyped by using the LightCycler™ System. ADMA was initially compared across the genetic variables using one-way ANOVA and then multivariate analysis examined each of the genes after adjustment for parameters of systemic inflammation and insulin resistance, namely erythrocyte sedimentation rate (ESR) and homeostatic model assessment (HOMA), which we have previously shown affect ADMA levels in RA.
RESULTS: No significant relationship between DDAH genetic variables and ADMA levels was established in ANOVA analysis. Multivariate model adjusted for age, HOMA and ESR did not demonstrate any significant association between DDAH variants and ADMA.
CONCLUSION: The results of our study give no evidence to suggest that increased ADMA levels in RA relate to DDAH genetic polymorphisms. Better understanding of disease-related factors and their interactions with traditional CV risk factors may represent mechanisms responsible for ADMA accumulation in this population.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ADMA; CV disease; DDAH; Rheumatoid arthritis

Mesh:

Substances:

Year:  2014        PMID: 25194333     DOI: 10.1016/j.atherosclerosis.2014.07.033

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

1.  A prospective, longitudinal monocentric study on laser Doppler imaging of microcirculation: comparison with macrovascular pathophysiology and effect of adalimumab treatment in early rheumatoid arthritis.

Authors:  László Dávida; Vanda Pongrácz; Emir Awad Mohamed; Szilvia Szamosi; Gabriella Szücs; Andrea Váncsa; Orsolya Tímár; Zoltán Csiki; Edit Végh; Pál Soltész; Zoltán Szekanecz; György Kerekes
Journal:  Rheumatol Int       Date:  2019-12-19       Impact factor: 2.631

Review 2.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

Review 3.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

Review 4.  Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis.

Authors:  Manuela Di Franco; Bruno Lucchino; Fabrizio Conti; Guido Valesini; Francesca Romana Spinelli
Journal:  Mediators Inflamm       Date:  2018-01-18       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.